Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, “which we are unable to predict at this time.” ...

Pfizer expanded its cost-cutting plans and posted first-quarter profit above estimates, despite a decline in sales driven by ...

Pfizer (NYSE:PFE) surged about 3% on Tuesday ... Management reaffirmed its full-year 2025 outlook, noting that the forecast does not currently include any potential impact related to future ...

The company forecast 2025 sales of between $61 billion and $64 billion ... but also currently trending toward the upper end of its adjusted earnings outlook for the year. Pfizer generated record ...

Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3. StockStory aims to help individual investors beat the market.

Pfizer ( PFE) reported mixed first quarter earnings Tuesday, as the company struggles to gain investor interest in its ...

Photo: ABC News Pfizer ... outlook for the year, and announced another round of cost cuts as the beleaguered drugmaker looks to turn around its business postpandemic. The company forecast 2025 ...

Pfizer on Tuesday expanded its cost-cutting efforts and reported first-quarter profit that topped ... Pfizer did not revise its outlook. The company maintained its full-year 2025 outlook ...